Track market-moving stories before they get noisy

Tyler Technologies (TYL - Free Report) came out with quarterly earnings of $3.08 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $2.91 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +0.65%. A quarter ago, it was expected that this information management software provider would post earnings of $3.01 per share when it actually produced earnings of $3.09, delivering a surprise of +2.66%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Tyler Technologies, which belongs to the Zacks Internet - Software and Services industry, posted revenues of $645.1 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $596.12 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Tyler Technologies shares have lost about 26.6% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Tyler Technologies?While Tyler Technologies has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Tyler Technologies was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.37 on $652.97 million in revenues for the coming quarter and $12.82 on $2.56 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Internet - Software and Services is currently in the top 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Nebius Group (NBIS - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.

This an AI-centric cloud platform is expected to post quarterly loss of $0.67 per share in its upcoming report, which represents a year-over-year change of -76.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Nebius Group's revenues are expected to be $535.03 million, up 409.1% from the year-ago quarter.

Aurora Innovation, Inc. (AUR) Q2 2026 Earnings Call July 29, 2026 5:00 PM EDT

Company Participants

Stacy Feit - Vice President of Investor Relations
Christopher Urmson - Co-Founder, CEO & Non-Independent Executive Chairman
David Maday - Chief Financial Officer

Conference Call Participants

George Gianarikas - Canaccord Genuity Corp., Research Division
Ravi Shanker - Morgan Stanley, Research Division
Andres Sheppard-Slinger - Cantor Fitzgerald & Co., Research Division
Christopher Pierce - Needham & Company, LLC, Research Division
Ryan Sigdahl - Craig-Hallum Capital Group LLC, Research Division
Colin Rusch - Oppenheimer & Co. Inc., Research Division
Cole Couzens - Wolfe Research, LLC
Mike Latimore - Northland Capital Markets, Research Division
Itay Michaeli - TD Cowen, Research Division
Aman Gupta - Goldman Sachs Group, Inc., Research Division
Justine Laufer - Bernstein Institutional Services LLC, Research Division

Presentation

Operator

Greetings, and welcome to the Aurora Second Quarter 2026 Business Review Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce Stacy Feit, Vice President, Investor Relations. You may now begin.

Stacy Feit
Vice President of Investor Relations

Thanks, Paul. Good afternoon, everyone, and welcome to our second quarter 2026 business review call. We announced our results earlier this afternoon. Our shareholder letter and a presentation to accompany this call are available on our Investor Relations website at ir.aurora.tech. The shareholder letter was also furnished with our Form 8-K filed today with the SEC.

On the call with me today are Chris Urmson, Co-Founder and CEO; and David Maday, CFO. Chris will provide an update on the progress we've made across the key pillars of our business, and David will recap our second quarter financial results. We'll then open up the call to Q&A. A recording of this conference call will be available on our Investor Relations website at ir.aurora.tech shortly after this call has ended.

I'd like

3 Small Caps Hitting 52-Week Highs: Take Profits or Let Ride?Sonos NASDAQ: SONO reported third-quarter fiscal 2026 revenue of $375 million, up 9% from a year earlier and near the high end of its guidance range, as growth in Asia-Pacific and Europe, the Middle East and Africa offset more modest gains in the Americas.

CEO Tom Conrad said the quarter reflected an acceleration in the company’s growth trajectory after revenue rose 2% in the first half of the fiscal year. Non-GAAP gross margin was 45.5%, while adjusted EBITDA reached $44 million, up 24% year over year. The company also repurchased $30 million of stock during the quarter.

Get Sonos alerts:

Regional Growth and Profitability MarketBeat: Week in Review 5/30 – 6/3CFO Saori Casey said APAC revenue increased 27% year over year, EMEA revenue rose 17%, and Americas revenue grew 4%. On a constant-currency basis, APAC grew 21%, EMEA increased 14%, and the Americas rose 3.5%. Foreign exchange contributed about one percentage point to reported growth.

Casey said Sonos Play and Era 100 SL, which were available for the full quarter, contributed meaningfully to results. The company’s non-GAAP gross profit rose 11% to $171 million. However, higher memory costs reduced gross profit by about $14 million year over year, representing a 380-basis-point impact on gross margin.

Sonos Stock Sounds Cheap Down HereSonos received $24 million during the quarter related to refunds for duties paid under IEEPA. Of that amount, $23 million was recorded as a benefit to GAAP gross profit and $1 million was recorded as interest income. The company has filed claims totaling $41 million and expects to collect the remaining $18 million, though it has not recognized those amounts as a receivable because the timing of payment is uncertain.

Including tariff refunds, GAAP gross profit was $189 million and GAAP gross margin was 50.4%. Excluding refunds, GAAP gross margin was 44.3%. GAAP earnings per share were $0.25, including a $0.20 benefit from tariff refunds, compared with a loss of $0.03 per share a year earlier. Non-GAAP EPS rose 52% to $0.27.

Non-GAAP operating expenses increased 3% year over year to $135 million. The company ended the quarter with $261 million of net cash and marketable securities. Free cash flow was $40 million, up $8 million from the prior-year period.

Memory Costs Pressure Outlook Management said escalating computer-memory and related component costs are expected to remain a near-term challenge. Conrad said higher memory costs reduced third-quarter adjusted EBITDA by approximately $14 million. Without that impact, adjusted EBITDA would have been $58 million, up 64% year over year.

For the fourth quarter, Sonos expects higher memory prices to create a $35 million year-over-year headwind to gross profit, or roughly 1,000 basis points of gross-margin pressure. The company expects mitigation efforts to phase in progressively through fiscal 2027.

Conrad said Sonos is addressing the issue through supply management, cost negotiations, engineering changes intended to reduce each product’s memory requirements, and potential pricing actions. He said the efficiency work can be implemented as running changes to product lines without reducing product capabilities, future optionality or customer experience.

The company has not made material price increases on existing audio products. Conrad said Sonos remains focused on attracting new households during the holiday period, while considering pricing as one of several available levers. Management expects profitability to improve in fiscal 2028 and beyond, depending in part on the path of memory prices.

Fourth-Quarter and Full-Year Expectations Sonos forecast fourth-quarter revenue of $325 million to $355 million, representing reported growth of 13% to 23%, or 18% at the midpoint. The fiscal fourth quarter includes an extra week, which the company said should contribute approximately $24 million in sales and eight percentage points of year-over-year growth.

Excluding the additional week, the outlook implies revenue growth of 4% to 15%, or 10% at the midpoint. Management expects foreign exchange to have a slightly unfavorable effect on fourth-quarter revenue growth.

Fourth-quarter GAAP gross margin is expected to be 39% to 41%, excluding any tariff-refund benefit. Non-GAAP gross margin is expected to be approximately 120 basis points above GAAP gross margin. Adjusted EBITDA is projected between a loss of $11 million and positive $18 million, with a midpoint of $3 million. Fiscal 2026 revenue is expected to grow 6% to 8%, or 4% to 6% excluding the 53rd week. Fiscal 2026 adjusted EBITDA is expected to reach $181 million, up 37% year over year. For fiscal 2027, Casey said the low end of the company’s fourth-quarter gross-margin range is a reasonable framework for the year, with lower margins in the first half and some improvement in the second half as mitigation efforts take effect. She also said Sonos expects to remain disciplined on operating expenses.

Products, AI Focus and Leadership Changes Conrad said Sonos Amp Multi, a multi-zone amplifier aimed at installer and integrator partners, is scheduled to ship Aug. 25. He also said the company plans a product launch event in early September, where it intends to discuss work involving conversational computing and predictive intelligence in the home.

The CEO said Sonos’ installed base includes more than 53 million connected devices across more than 17 million homes. He argued that the company’s portfolio, audio expertise, home-system integrations and customer relationships position it to benefit as more intelligence is incorporated into home products.

Separately, Sonos said Chris Shackleton, co-founder and managing partner of Coliseum Capital Management, the company’s largest investor, will join its board.

Casey also announced plans to retire following a 35-year finance career. She will remain CFO until the company identifies a successor and completes a transition. Conrad said she helped establish financial rigor and operating discipline at Sonos during her tenure.

About Sonos (NASDAQ:SONO)Sonos, Inc is a consumer electronics company specializing in wireless home audio systems. The company's core business revolves around designing, developing and manufacturing smart speakers and soundbars that deliver high-fidelity audio and seamless multi-room listening experiences. Sonos products connect via Wi-Fi or Bluetooth and integrate with popular streaming services, enabling users to control music and other audio content through a dedicated mobile app, voice assistants or traditional controls.

Sonos offers a diversified product lineup that includes compact speakers such as Sonos One and Sonos Roam, premium models like Sonos Five and Sonos Move, home theater solutions including Sonos Beam and Sonos Arc, as well as accessories such as the Sonos Sub and Sonos Amp.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Sonos Right Now?Before you consider Sonos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sonos wasn't on the list.

While Sonos currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Everest Group (EG - Free Report) came out with quarterly earnings of $14.85 per share, beating the Zacks Consensus Estimate of $14.59 per share. This compares to earnings of $17.36 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +1.78%. A quarter ago, it was expected that this reinsurance company would post earnings of $14.03 per share when it actually produced earnings of $16.08, delivering a surprise of +14.61%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Everest Group, which belongs to the Zacks Insurance - Multi line industry, posted revenues of $3.96 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 3.07%. This compares to year-ago revenues of $4.49 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Everest Group shares have added about 17.5% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Everest Group?While Everest Group has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Everest Group was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $9.21 on $3.96 billion in revenues for the coming quarter and $52.86 on $15.89 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Insurance - Multi line is currently in the bottom 32% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Horace Mann (HMN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 5.

This provider of auto and homeowners' insurance for teachers and other educators is expected to post quarterly earnings of $0.67 per share in its upcoming report, which represents a year-over-year change of -36.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Horace Mann's revenues are expected to be $443.9 million, up 7.8% from the year-ago quarter.

Cactus, Inc. (WHD - Free Report) reported $449.53 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 64.3%. EPS of $0.93 for the same period compares to $0.66 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $400.62 million, representing a surprise of +12.21%. The company delivered an EPS surprise of +30.99%, with the consensus EPS estimate being $0.71.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Cactus performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Revenues- Spoolable Technologies: $105.53 million compared to the $96 million average estimate based on four analysts. The reported number represents a change of +9.7% year over year.Revenues- Pressure Control: $344 million compared to the $306.29 million average estimate based on four analysts. The reported number represents a change of +91.4% year over year.Operating income (loss)- Pressure Control: $59.15 million versus $50.97 million estimated by three analysts on average.Operating Income- Corporate and other expenses: $-7.74 million compared to the $-9.81 million average estimate based on three analysts.Operating income (loss)- Spoolable Technologies: $32.17 million compared to the $23.96 million average estimate based on three analysts.View all Key Company Metrics for Cactus here>>>

Shares of Cactus have returned +3.7% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Insperity, Inc. (NSP - Free Report) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +3.03%. A quarter ago, it was expected that this company would post earnings of $1.24 per share when it actually produced earnings of $1.31, delivering a surprise of +5.65%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Insperity, which belongs to the Zacks Staffing Firms industry, posted revenues of $1.69 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.50%. This compares to year-ago revenues of $1.66 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Insperity shares have added about 35.8% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Insperity?While Insperity has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Insperity was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.22 on $1.63 billion in revenues for the coming quarter and $2.07 on $6.89 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Staffing Firms is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Kelly Services (KELYA - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This staffing company is expected to post quarterly earnings of $0.24 per share in its upcoming report, which represents a year-over-year change of -55.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Kelly Services' revenues are expected to be $1.01 billion, down 8.4% from the year-ago quarter.

Glaukos (GKOS - Free Report) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.3 per share when it actually produced a loss of $0.18, delivering a surprise of +40%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Glaukos, which belongs to the Zacks Medical - Instruments industry, posted revenues of $185.61 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 24.10%. This compares to year-ago revenues of $124.12 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Glaukos shares have added about 34% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Glaukos?While Glaukos has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Glaukos was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.16 on $154.92 million in revenues for the coming quarter and -$0.57 on $627.64 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Hyperfine, Inc. (HYPR - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of +25%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Hyperfine, Inc.'s revenues are expected to be $4.23 million, up 56.7% from the year-ago quarter.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Graphic Packaging Holding Company (NYSE: GPK), a global leader in sustainable consumer packaging, today announced that its Board of Directors declared a quarterly dividend of $0.11 per share of common stock to stockholders of record at the close of business on September 15, 2026. The dividend is payable on October 6, 2026.

Investor Contact Information: [email protected]

About Graphic Packaging Holding Company
Graphic Packaging (NYSE: GPK), headquartered in Atlanta, Georgia, designs and produces consumer packaging made primarily from renewable or recycled materials. An industry leader in innovation, the Company is committed to reducing the environmental footprint of consumer packaging. Graphic Packaging operates a global network of design and manufacturing facilities serving the world's most widely recognized brands in food, beverage, foodservice, household, and other consumer products. Learn more at www.graphicpkg.com.

SOURCE Graphic Packaging Holding Company

Also from this source

Tetra Tech (TTEK - Free Report) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.4 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.00%. A quarter ago, it was expected that this consulting and engineering services company would post earnings of $0.31 per share when it actually produced earnings of $0.34, delivering a surprise of +9.68%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Tetra, which belongs to the Zacks Engineering - R and D Services industry, posted revenues of $1.11 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.60%. This compares to year-ago revenues of $1.15 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Tetra shares have lost about 0.1% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Tetra?While Tetra has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Tetra was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.47 on $1.15 billion in revenues for the coming quarter and $1.55 on $4.31 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Engineering - R and D Services is currently in the top 34% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Mayville Engineering (MEC - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.

This company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of -180%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Mayville Engineering's revenues are expected to be $149.69 million, up 13.1% from the year-ago quarter.

Sensata (ST - Free Report) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.87 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.38%. A quarter ago, it was expected that this maker of sensing, electrical protection, control and power management products would post earnings of $0.84 per share when it actually produced earnings of $0.86, delivering a surprise of +2.38%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Sensata, which belongs to the Zacks Instruments - Control industry, posted revenues of $990.6 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 2.76%. This compares to year-ago revenues of $943.38 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Sensata shares have added about 40.4% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Sensata?While Sensata has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Sensata was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.95 on $962 million in revenues for the coming quarter and $3.73 on $3.86 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Instruments - Control is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Transcat, Inc. (TRNS - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.

This company is expected to post quarterly earnings of $0.37 per share in its upcoming report, which represents a year-over-year change of -37.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Transcat, Inc.'s revenues are expected to be $86.42 million, up 13.1% from the year-ago quarter.

C.H. Robinson Worldwide (CHRW - Free Report) came out with quarterly earnings of $1.61 per share, beating the Zacks Consensus Estimate of $1.53 per share. This compares to earnings of $1.29 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.23%. A quarter ago, it was expected that this trucking company would post earnings of $1.24 per share when it actually produced earnings of $1.35, delivering a surprise of +8.87%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

C.H. Robinson, which belongs to the Zacks Transportation - Services industry, posted revenues of $4.93 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 11.74%. This compares to year-ago revenues of $4.14 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

C.H. Robinson shares have added about 5.3% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for C.H. Robinson?While C.H. Robinson has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for C.H. Robinson was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.66 on $4.46 billion in revenues for the coming quarter and $6.12 on $17.11 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Transportation - Services is currently in the top 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Matson (MATX - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 3.

This ocean transportation and logistics services company is expected to post quarterly earnings of $3.74 per share in its upcoming report, which represents a year-over-year change of +28.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Matson's revenues are expected to be $906.81 million, up 9.2% from the year-ago quarter.

Comstock Resources (CRK - Free Report) reported $353.28 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 24.9%. EPS of $0.03 for the same period compares to $0.13 a year ago.

The reported revenue represents a surprise of -14.9% over the Zacks Consensus Estimate of $415.15 million. With the consensus EPS estimate being $0.02, the EPS surprise was +50%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Comstock performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Average oil price: $95.20 compared to the $82.19 average estimate based on three analysts.Average natural gas price: $2.54 versus the two-analyst average estimate of $2.58.Average natural gas price including hedging: $2.93 compared to the $2.98 average estimate based on two analysts.Revenues- Natural gas sales: $287.75 million versus the two-analyst average estimate of $307.16 million. The reported number represents a year-over-year change of -15.2%.Revenues- Oil sales: $0.48 million versus $0.87 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -35.8% change.View all Key Company Metrics for Comstock here>>>

Shares of Comstock have returned -17% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Churchill Downs (CHDN - Free Report) came out with quarterly earnings of $3.45 per share, missing the Zacks Consensus Estimate of $3.51 per share. This compares to earnings of $3.1 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -1.71%. A quarter ago, it was expected that this racetrack operator and gambling company would post earnings of $1.06 per share when it actually produced earnings of $1.21, delivering a surprise of +14.15%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Churchill Downs, which belongs to the Zacks Gaming industry, posted revenues of $980 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.34%. This compares to year-ago revenues of $934.4 million. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Churchill Downs shares have lost about 21.6% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for Churchill Downs?While Churchill Downs has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Churchill Downs was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.31 on $698.94 million in revenues for the coming quarter and $7.14 on $3.02 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Gaming is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Century Casinos (CNTY - Free Report) , has yet to report results for the quarter ended June 2026.

This casino operator is expected to post quarterly loss of $0.40 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Century Casinos' revenues are expected to be $152.1 million, up 0.9% from the year-ago quarter.

For the quarter ended June 2026, Hexcel (HXL - Free Report) reported revenue of $529.3 million, up 8% over the same period last year. EPS came in at $0.66, compared to $0.50 in the year-ago quarter.

The reported revenue represents a surprise of +1.47% over the Zacks Consensus Estimate of $521.65 million. With the consensus EPS estimate being $0.56, the EPS surprise was +17.86%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Hexcel performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Net Sales- Commercial Aerospace- Composite Materials: $289.2 million versus $279.43 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +15.7% change.Net Sales- Defense, Space & Other- Composite Materials: $132.3 million compared to the $135.25 million average estimate based on two analysts. The reported number represents a change of -7.7% year over year.Net Sales- Engineered products: $107.8 million versus $102.89 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +11.5% change.Net Sales- Defense, Space & Other- Engineered Products: $50.4 million versus the two-analyst average estimate of $54.12 million. The reported number represents a year-over-year change of -5.8%.Net Sales- Composite Materials: $421.5 million compared to the $414.67 million average estimate based on two analysts. The reported number represents a change of +7.2% year over year.Net Sales- Commercial Aerospace- Engineered Products: $57.4 million versus the two-analyst average estimate of $48.77 million. The reported number represents a year-over-year change of +32.9%.Operating income- Composite Materials: $74.2 million compared to the $73.31 million average estimate based on two analysts.Operating income- Corporate & Other: $-18 million compared to the $-18.11 million average estimate based on two analysts.Operating income- Engineered Products: $16.4 million versus the two-analyst average estimate of $8.57 million.View all Key Company Metrics for Hexcel here>>>

Shares of Hexcel have returned +10% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Michael N. Intrator, CEO and President of CoreWeave, Inc. (CRWV -9.63%), reported the sale of 307,692 shares of Class A Common Stock on July 14, 2026, for a total transaction value of ~$24.9 million, according to a recent SEC Form 4 filing.

Transaction summaryMetricValueTransaction value~$24.9 millionShares sold307,692Shares sold (directly held)200,000Shares sold (indirectly held)107,692Post-transaction shares (directly held)2,676,815Post-transaction shares (indirectly held)0Post-transaction value$213.98 millionTransaction value based on SEC Form 4 weighted average sale price ($80.85); post-transaction value based on July 14, 2026 market close ($79.94).

Key questionsWhat was the context for this transaction?
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Michael Intrator on November 20, 2025. These plans allow insiders to schedule stock sales in advance to avoid potential conflicts regarding the possession of non-public material information.How did the transaction impact the insider’s indirect ownership entities?
The disposition included 107,692 shares held indirectly by Omnadora Capital LLC, effectively liquidating the firm's Class A Common Stock position. The insider continues to hold indirect interests through other entities, including the PMI 2024 F&F GRAT, the Intrator Family GST-Exempt Trust, and the Intrator Family Trust.What is the scale of the insider’s remaining equity exposure?
Following the sale, the CEO maintains a direct holding of 2,676,815 shares, representing approximately 0.49% of the company. Furthermore, Intrator holds substantial derivative securities, including 21.9 million direct and 30.6 million indirect options outstanding, which include both vested and unvested awards.How has the stock performed relative to this transaction?
As of the July 15, 2026 market close, shares were priced at $77.12, trailing the $80.85 execution price. On the July 14, 2026 transaction date, CoreWeave had a one-year total return of -40% and a market capitalization of $42.1 billion.Company OverviewMetricValueShare Price (as of market close 2026-07-15)$77.12Market Capitalization$42.1 billionRevenue (TTM)$6.2 billionNet Income (TTM)-$1.6 billionCompany SnapshotCoreWeave operates a specialized cloud computing platform that delivers high-performance GPU and CPU compute resources, storage solutions, advanced networking capabilities, and fully managed services designed to support generative AI and intensive compute workloads for enterprise clients.The company generates revenue through a flexible consumption-based model, offering clients the choice between virtual servers and bare-metal infrastructure solutions tailored to their specific computational requirements.CoreWeave primarily serves large enterprises and organizations requiring significant computational capacity for generative AI applications, machine learning workloads, and data-intensive processing operations.CoreWeave is a leading infrastructure provider for generative AI workloads, commanding a $42.1 billion market cap. The company has established itself as a critical enabler of enterprise AI adoption by providing purpose-built cloud infrastructure optimized for GPU-accelerated computing.

Despite current net losses reflecting the capital-intensive nature of infrastructure expansion, CoreWeave's significant revenue scale and strategic positioning in the high-growth generative AI market underscore its importance as a foundational technology provider.

What this transaction means for investorsCoreWeave CEO Michael Intrator’s July 14 sale of company stock for a weighted average price of $80.85 came at a time when the stock had plunged from its 52-week high of $153.20 reached last October, and continued to fall. Shares eventually dropped to a 52-week low of $60.55 on July 29.

However, Intrator’s sale is not necessarily a cause for investor concern given it was a non-discretionary transaction executed as part of a Rule 10b5-1 trading plan. Moreover, his substantial equity holdings totaling millions of shares suggest his interests remain aligned with shareholders.

It appears Intrator, through his ownership of Omnadora Capital LLC, converted some Class B shares into Class A and sold them, reducing Omnadora Capital’s Class A holdings to zero. However, this entity maintains over 23 million Class B shares, post-sale.

CoreWeave stock has fallen as rising credit default swap costs signal heightened risk that the company may default on its billions of dollars in debt. CoreWeave took on the debt to enable construction of data centers outfitted with costly tech infrastructure to support customers seeking computing capacity to run artificial intelligence systems.

Robert Izquierdo has positions in CoreWeave. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

FTAI Aviation (FTAI - Free Report) came out with quarterly earnings of $1.13 per share, missing the Zacks Consensus Estimate of $1.32 per share. This compares to earnings of $1.57 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -14.39%. A quarter ago, it was expected that this transportation infrastructure company would post earnings of $1.61 per share when it actually produced earnings of $1.29, delivering a surprise of -19.88%.

Over the last four quarters, the company has not been able to surpass consensus EPS estimates.

FTAI Aviation, which belongs to the Zacks Aerospace - Defense Equipment industry, posted revenues of $953.09 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 10.91%. This compares to year-ago revenues of $676.24 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

FTAI Aviation shares have added about 7.9% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for FTAI Aviation?While FTAI Aviation has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for FTAI Aviation was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.54 on $904.99 million in revenues for the coming quarter and $6.77 on $3.72 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Aerospace - Defense Equipment is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, AerSale Corporation (ASLE - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 6.

This company is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of -80%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

AerSale Corporation's revenues are expected to be $77.48 million, down 27.9% from the year-ago quarter.

In June, Meta entered the enterprise AI market with a new AI agent aimed at businesses, to help with customer service, support, and other daily operations. But the tech giant’s enterprise AI ambitions are much more expansive, Meta CEO Mark Zuckerberg told investors on Wednesday’s second-quarter earnings call.

“We see a large enterprise opportunity to sell to businesses, including APIs, business agents, potentially selling compute directly, and other services that we’re building for large customers,” Zuckerberg said. These additions could potentially position the business to create new revenue streams beyond advertising, which drives the bulk of its business, and subscriptions, which contribute a smaller share.

Initially, the company will focus on the opportunity to serve its existing base of advertisers by offering AI agents that work across messaging apps and elsewhere. These allow businesses to interact with their own customers through an AI interface.

“And, just like the ad system, effectively, we will get paid when we deliver results for those businesses,” Zuckerberg said. “We view this as an extension of the sales and the partnerships that we have with many millions of advertisers and hundreds of millions of small businesses that use our platforms.”

He also fleshed out how Meta could expand beyond serving the small business customer that makes up much of its current advertiser base by offering Meta’s internal tools to external customers in the future.

“There are other enterprise customers who I think we’re increasingly going to serve, too,” Zuckerberg explained. “We’re building coding and developing and internal productivity tools partially because we need to build them ourselves, and we need to make sure that we have tools that are tuned for ourselves,” he continued. “Now that we have those, we feel like there’s a large opportunity to serve — whether that’s small businesses or larger businesses.”

This shift in focus may not come easy — Zuckerberg admitted that selling to the enterprise was a “different muscle” than the one Meta has historically flexed.

Meanwhile, in terms of Meta selling compute to enterprise customers, Meta is focused on balancing its need for revenue and its need to execute on its own future plans. That said, the company pointed out multiple times that it currently has the opportunity to sell compute at “a significant premium over what we paid for it.”

Still, Zuckerberg cautioned investors that it “would be foolish” to “sell all of the compute and take a short-term profit.” Instead, he described Meta’s approach as a “portfolio” that included a mix of long-term and short-term plans for its compute infrastructure. “As we get closer to personal superintelligence, we are . . . going to need hardware that allows you to seamlessly interact with it,” he noted.

The call also focused on Meta’s sizable ambitions around agentic AI — AI systems that can act on a person’s or business’ behalf, rather than just answer questions — which won’t only be offered to businesses.

Consumers, too, are being promised “personal AI agents,” as well as AI smart glasses that can interact with the world in front of them.

Plus, Meta is using AI technology — specifically, large language models — to more rapidly build out its suite of social apps. Recent launches on this front have included an app for Marketplace sellers, another for Facebook Groups, one for vibe-coded games, and other experiments. More are on the way, Zuckerberg teased.

“I expect it to become a lot easier to ship new apps,” said Zuckerberg. “So we are planning to build out more ideas and use our recommendation systems to scale them to the people who will find them interesting.”

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Sarah has worked as a reporter for TechCrunch since August 2011. She joined the company after having previously spent over three years at ReadWriteWeb. Prior to her work as a reporter, Sarah worked in I.T. across a number of industries, including banking, retail and software.

You can contact or verify outreach from Sarah by emailing [email protected] or via encrypted message at sarahperez.01 on Signal.

by Todd Bishop on Jul 29, 2026 at 4:38 pmJuly 29, 2026 at 4:50 pm

Swami Sivasubramanian on stage at AWS re:Invent in 2023, with a keynote slide behind him. (GeekWire Photo / Todd Bishop) Amazon just broadened the role of Swami Sivasubramanian, the VP behind AWS’s agentic AI push, expanding and renaming his organization to include emerging technologies, and giving him a larger mandate to shape AI strategy and technical direction across the cloud division.

Sivasubramanian announced the change in a LinkedIn post on Wednesday, saying he will now lead the “Agentic AI & Emerging Technologies” organization, with an expanded title to match.

He described emerging technologies as “the work that doesn’t fit neatly into a team because it doesn’t exist yet.” It’s a type of work he’s done before, including formative roles with DynamoDB, now one of AWS’s most widely used databases, and Bedrock, the platform through which AWS customers access AI models from Anthropic, Meta, and others.

“When the industry is changing this quickly, it’s important to step back, pressure-test ideas, and see the big picture to help teams scale their impact,” he wrote.

Sivasubramanian’s agentic AI division has operated as a test case for running Amazon like a startup, with small teams shipping products in months that once took a year, as GeekWire reported in June.

He’ll continue overseeing the teams behind Kiro, Amazon Quick, and AWS Transform, while taking on new areas including neurosymbolic AI and a recently announced service called AWS Context, which builds a knowledge graph from a company’s existing data so AI agents can query it.

The expansion builds on moves already underway, including the hiring in May of former Microsoft security exec Shawn Bice to lead AWS’s Automated Reasoning Group, which uses mathematical techniques to verify that AI agents are doing what they’re supposed to do.

It also coincides with a broader reshuffling of Amazon’s AI strategy and teams.

Amazon laid off employees in its artificial general intelligence organization last week and confirmed the closure of its San Francisco AGI site, but noted that its frontier model research will continue under Pieter Abbeel, who joined Amazon through its acquisition of robotics startup Covariant.

Business Insider reported Monday that Amazon is winding down most of its in-house Nova foundation models, including its high-end Premier and Omni models, and concentrating engineering talent and computing resources on a smaller number of frontier efforts.

Sivasubramanian’s expanded role is separate from the AGI changes, and the two organizations operate independently of one another within Amazon. But the net effect is that Amazon is narrowing its work in frontier models while expanding its efforts in AI applications and services.

This mirrors a larger pattern across the industry, as big AI providers look to ensure the billions they’re sinking into chips and data centers pay off in customer outcomes and business growth.

In Brief

Posted:

3:46 PM PDT · July 29, 2026

Image Credits:Justin Sullivan / Getty Images When Microsoft reported killer fourth-quarter earnings for its fiscal 2026 year (which ended June 30), it tucked in an interesting little tidbit about how its investments in the two biggest, and competing, AI labs are doing.

For the quarter, it recorded its investment in Anthropic as a $3.2 billion gain, boosting diluted earnings per share by 33 cents. (Microsoft reported diluted earnings per share of $4.81 for the quarter). Microsoft invested $5 billion in Anthropic in November 2025 as part of a circular agreement under which the AI lab also agreed to buy $30 billion worth of Azure services.

Microsoft does not routinely update the value of its Anthropic investment each quarter. It does, however, discuss its OpenAI investment quarterly. Microsoft said investment did not fare nearly as well in the quarter, and marked it down about $600 million, reducing diluted EPS by about 7 cents per share.

Microsoft owns about 27% of OpenAI. And while Microsoft also receives revenue-share payments, it doesn’t report how much OpenAI pays under that arrangement. Instead, Microsoft accounts for the value of its investment. While this quarter brought a pretty sizable decline in the value of that investment, the $600 million write-down was still mostly a rounding error for Microsoft. The company delivered a highly profitable quarter, reporting $90 billion of revenue and net income of $35.8 billion for the quarter. Microsoft’s revenue was $331.8 billion with a net income of $133.7 billion for the year.

Microsoft’s OpenAI investment looks much better when viewed on a full-year basis.

For the year, Microsoft’s OpenAI investment generated a $5 billion gain and added $0.67 on EPS, respectively, the company reported. (Microsoft reported $17.95 EPS for its fiscal year.) Still, it is noteworthy that Microsoft reported nearly as much of a gain on Anthropic in one quarter as it did for the year on OpenAI. In fact, it is so noteworthy that Microsoft disclosed it.

Topics

Subscribe for the industry’s biggest tech news

Latest in AI

General Motors (GM - Free Report) ) and Ford Motor (F - Free Report) ) have both delivered better-than-expected second-quarter results, reinforcing the resilience of Detroit's legacy automakers despite a challenging backdrop that includes tariffs, slowing EV demand, and elevated interest rates.

Better pricing, disciplined cost controls, and continued strength in trucks and SUVs helped both companies top Wall Street's expectations while raising their full-year outlooks.

Following their upbeat Q2 reports, investors may be wondering whether the recent rally in both stocks has further room to run, with GM spiking 18% this month and F up 11%.

Image Source: Zacks Investment Research

GM Continues to Execute at a High LevelReporting Q2 results last week, General Motors once again demonstrated why it has become one of the auto industry's most consistent earnings performers.

General Motors reported Q2 revenue of $48.02 billion, up nearly 2% year over year and comfortably exceeding estimates of $46.55 billion by 3%.

More impressively, Q2 adjusted EPS of $3.57 soared 41% from earnings of $2.53 per share in the prior year quarter and crushed expectations of $3.13.

Image Source: Zacks Investment Research

GM raised its full-year guidance for the second time this year across several key metrics, increasing its adjusted EBIT (Earnings Before Interest and Taxes) outlook to a range of $14 billion to $16 billion, raising its adjusted EPS guidance to $12 to $14, and boosting its adjusted automotive free cash flow forecast to between $9.5 billion and $11.5 billion.

Operationally, North America remained the primary profit engine. GM generated an impressive 8.6% adjusted EBIT margin in the region, benefiting from continued demand for its full-size pickup trucks and SUVs, disciplined pricing, lower warranty costs, and improving EV profitability. Management also highlighted record adoption of its Super Cruise driver-assistance technology and improving efficiency across its manufacturing footprint.

These results suggest GM's strategy of balancing traditional internal combustion vehicles with a more measured EV transition is paying off. It’s also noteworthy that in the current global automotive landscape, a healthy EBIT margin for an automaker is generally considered to be in the low single digits.

Illustrating strong operational profitability and efficiency, GM’s trailing 12-month EBIT margin is at an industry-leading 5.78%, with Ford’s being roughly on par with the Zacks Automotive-Domestic Industry average of 2.81%.

Image Source: Zacks Investment Research

Ford Delivers an Encouraging QuarterFord also impressed investors with an earnings beat and a higher full-year outlook after reporting Q2 results yesterday evening.

Adjusted EPS came in at $0.42, rising from $0.37 per share a year ago and beating expectations of $0.33 by 27%.

Ford's operational performance remained encouraging, as adjusted EBIT climbed 17% YoY to $2.5 billion, highlighting the benefits of stronger pricing, a favorable product mix, and improving cost discipline.

This was despite Q2 revenue of $44.89 billion falling from $46.94 billion in the prior year quarter and missing estimates of $45.71 billion. That said, the company capitalized on a richer mix of high-margin trucks and SUVs while improving cost controls amid slower volume sales, which were attributed to discontinued vehicle models such as the Ford Escape.

Ford raised its full-year adjusted EBIT forecast to $10 billion-$11 billion, up from $8.5 billion-$10.5 billion, while also increasing its free cash flow outlook by roughly $1 billion to a range of $10 billion-$11 billion. Managment cited improving U.S. vehicle pricing, recovering aluminum supplies, and expected tariff refunds as key drivers behind the stronger outlook.

Image Source: Zacks Investment Research

GM & Ford Valuation ComparisonDespite their impressive rallies, both stocks remain inexpensive compared to the broader market.

GM continues to trade at a significant discount to the S&P 500, offering one of the lowest forward earnings multiples among large-cap industrial companies at 6X. Given General Motors improving earnings outlook, expanding margins, and strong free cash flow generation, that discount may prove difficult to justify if execution remains consistent.

Ford is also attractively valued at 9X forward earnings, although the market appears to be assigning a modest premium relative to GM because of its improving profitability and generous shareholder returns.

Image Source: Zacks Investment Research

To that point, Ford's dividend remains an added attraction for income-oriented investors at 4.01% compared to GM’s 0.8%. Still, GM's accelerating earnings growth and aggressive share repurchases have arguably created greater shareholder value in recent years.

Image Source: Zacks Investment Research

Conclusion & Final Thoughts GM and Ford both demonstrated that legacy automakers can still generate impressive earnings growth despite ongoing uncertainty surrounding tariffs, EV demand, and the broader economy.

For investors seeking the stronger combination of earnings momentum, improving profitability, and an attractive valuation, GM appears to have the edge following its impressive Q2 performance and second guidance increase of the year.

However, Ford's raised outlook, improving execution, and shareholder-friendly capital return strategy continue to make it an appealing long-term investment as well.

Supported by improving fundamentals and continued upward earnings estimate revisions, GM stock currently sports a Zacks Rank #2 (Buy), while Ford shares land a Zacks Rank #3 (Hold).

Starbucks Corporation (SBUX) Q3 2026 Earnings Call July 29, 2026 4:15 PM EDT

Company Participants

Catherine Park - Vice President of Investor Relations
Brian Niccol - Chairman & CEO
Catherine Smith - Executive VP & CFO

Conference Call Participants

David Tarantino - Robert W. Baird & Co. Incorporated, Research Division
David Palmer - Evercore ISI Institutional Equities, Research Division
Andrew Charles - TD Cowen, Research Division
Sara Senatore - BofA Securities, Research Division
Brian Harbour - Morgan Stanley, Research Division
Danilo Gargiulo - Bernstein Institutional Services LLC, Research Division
Zachary Fadem - Wells Fargo Securities, LLC, Research Division
John Ivankoe - JPMorgan Chase & Co, Research Division
Karen Holthouse
Margaret-May Binshtok - Wolfe Research, LLC
Logan Reich - RBC Capital Markets, Research Division
Stephen McManus - BNP Paribas, Research Division

Presentation

Operator

Good afternoon, and welcome to Starbucks' Third Quarter Fiscal Year 2026 Earnings Call. [Operator Instructions].

I will now turn the call over to Catherine Park, Vice President of Investor Relations. Ms. Park, you may now begin your conference.

Catherine Park
Vice President of Investor Relations

Good afternoon, and thank you for joining us today to discuss Starbucks' third quarter fiscal year 2026 results. Today's discussion will be led by Brian Niccol, Chairman and Chief Executive Officer; and Cathy Smith, Executive Vice President and Chief Financial Officer.

This conference call will include forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ from these statements. Any such statements should be considered in conjunction with cautionary statements in our earnings release and risk factors discussed in our filings with the SEC. Starbucks assumes no obligation to update any of these forward-looking statements or information.

Revenue, operating margin and EPS growth metrics referenced on today's call are non-GAAP and measured in constant currency. All other metrics referenced on today's call are non-GAAP. Please refer to the earnings

Daten zeigten, dass die COVID-19-Impfstoffformulierung für das Jahr 2026-2027, die gegen die XFG-Variante gerichtet ist, eine starke Immunantwort gegen derzeit zirkulierende und neu auftretende Virusvarianten generiertÜber fünf Milliarden Dosen der Pfizer-BioNTech COVID-19-Impfstoffe wurden bereits weltweit zur Verfügung gestelltDer Impfstoff zeigt ein vorteilhaftes Sicherheits- und WirksamkeitsprofilDer Versand wird zeitnah beginnen, um einen schnellen Zugang zu dem Impfstoff der aktuellen Saison zu gewährleisten  NEW YORK und MAINZ, Deutschland, 29. Juli 2026 — Pfizer Inc. (NYSE: PFE, „Pfizer“) und BioNTech SE (Nasdaq: BNTX, „BioNTech“) gaben heute bekannt, dass die Europäische Kommission („EK“) die Marktzulassung (Marketing Authorization) für die an die XFG-Variante angepasste COVID-19-Impfstoffformulierung der Unternehmen für die Impfsaison 2026-2027 erteilt hat. Die Zulassung gilt für die aktive Immunisierung zur Vorbeugung von COVID-19, verursacht durch SARS-CoV-2, bei Personen ab 6 Monaten. Die Anpassung basiert auf der Empfehlung der Notfall-Taskforce (Emergency Task Force, „ETF“) der Europäischen Arzneimittel-Agentur (European Medicines Agency, „EMA“), die vorschlägt, COVID-19-Impfstoffe für die Impfsaison 2026-2027 so anzupassen, dass sie gegen die XFG-Variante der JN.1-Linie gerichtet sind. Die Notfall-Taskforce erklärte: „Die Datenlage weist darauf hin, dass eine Anpassung an XFG den bestmöglichen Schutz gegen COVID-19 bieten sollte.“1

Die Marktzulassung ist in allen 27 Mitgliedsstaaten der Europäischen Union („EU“) sowie in Island, Liechtenstein und Norwegen gültig. Pfizer und BioNTech haben bereits auf eigenes Risiko mit der Herstellung des an XFG angepassten monovalenten COVID-19-Impfstoffs begonnen, um die Verfügbarkeit vor Beginn der bevorstehenden Erkältungssaison sicherzustellen, in der die Nachfrage nach COVID-19-Impfungen voraussichtlich steigen wird. Die EU-Mitgliedstaaten sowie Norwegen werden entweder im Rahmen des Vertrags mit der EK oder gemäß den jeweiligen nationalen Mechanismen der einzelnen Staaten beliefert.

Die Genehmigung der EK folgt auf die Empfehlung des Ausschusses für Humanarzneimittel (Committee for Medicinal Products for Human Use, „CHMP“) der EMA vom 23. Juli 2026, die auf der Gesamtheit der bisherigen von Pfizer und BioNTech vorgelegten Daten basiert. Die vorgelegten Daten beinhalten klinische und nicht-klinische Ergebnisse und Daten aus der praktischen Anwendung, die die Sicherheit und Wirksamkeit der COVID-19-Impfstoffe von Pfizer und BioNTech belegen, sowie Daten zur Herstellung/Qualität und nicht-klinische Daten, die zeigten, dass der an XFG angepasste monovalente COVID-19-Impfstoff starke Immunantworten gegen derzeit zirkulierende SARS-CoV-2-Linien generiert, darunter XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 und andere derzeit zirkulierende Linien.2

Die Unternehmen haben zudem Daten zum aktualisierten COVID-19-Impfstoff bei Zulassungsbehörden weltweit eingereicht. Pfizer und BioNTech beobachten weiterhin die Entwicklung der Epidemiologie von COVID-19, um auf die globalen Bedürfnisse im Bereich der öffentlichen Gesundheit vorbereitet zu sein.

Die COVID-19-Impfstoffe von Pfizer und BioNTech basieren auf BioNTechs unternehmenseigener mRNA-Technologie und wurden von beiden Unternehmen gemeinsam entwickelt. BioNTech ist Inhaber der Marktzulassung für die Impfstoffe in den Vereinigten Staaten, der Europäischen Union, dem Vereinigten Königreich, und anderen Ländern, sowie Inhaber von Notfallzulassungen und weiteren Zulassungen in anderen Ländern.

EU-ZUSAMMENFASSUNG DER PRODUKTCHARAKTERISTIKA

Hier finden Sie eine vollständige Übersicht der Produktcharakteristika für den Pfizer-BioNTech COVID-19-Impfstoff.

Wichtige Sicherheitsinformationen

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung.

COMIRNATY® XFG 30 Mikrogramm/Dosis Injektionsdispersion in einer Fertigspritze (Glas) (ab 12 Jahren): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Fertigspritze enthält 1 Dosis von 0,3 ml mit jeweils 30 Mikrogramm für XFG kodierender mRNA (eingebettet in Lipid-Nanopartikel). COMIRNATY® XFG 10 Mikrogramm/Dosis Injektionsdispersion (Säuglinge und Kinder von 6 Monaten–11 Jahren): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Durchstechflasche enthält 1 Dosis von 0,3 ml mit jeweils 10 Mikrogramm für XFG kodierender mRNA (eingebettet in Lipid-Nanopartikel). COMIRNATY® LP.8.1 30 Mikrogramm/Dosis Injektionsdispersion (gefrorene Durchstechflaschen) (ab 12 Jahre): Wirkstoff: COVID-19-mRNA-Impfstoff. Zusammensetzung: Eine Durchstechflasche enthält 6 Dosen von 0,3 ml mit jeweils 30 Mikrogramm für LP.8.1 kodierender mRNA (eingebettet in Lipid-Nanopartikel). Sonstige Bestandteile (in allen oben genannten COMIRNATY® Impfstoffen): ((4-Hydroxybutyl)azandiyl)bis(hexan-6,1-diyl)bis(2-hexyldecanoat) (ALC-0315), 2-[(Polyethylenglykol)-2000]-N,N-ditetradecylacetamid (ALC-0159), Colfoscerilstearat (DSPC), Cholesterol, Trometamol, Trometamolhydrochlorid, Saccharose, Wasser für Injektionszwecke. Anwendungsgebiete: Aktive Immunisierung zur Vorbeugung von COVID-19 durch SARS-CoV-2 bei Säuglingen und Kindern im Alter von 6 Monaten bis 11 Jahren (COMIRNATY® XFG 10 Mikrogramm in 0,3 ml), bzw. bei Personen ab 12 Jahren (COMIRNATY® XFG 30 Mikrogramm in 0,3 ml bzw. COMIRNATY® LP.8.1 30 Mikrogramm in 0,3 ml). Gegenanzeigen: Allergie gegen einen der Bestandteile des Arzneimittels. Nebenwirkungen: Sehr häufig: Schmerzen/Schwellung an der Injektionsstelle; Schmerzempfindlichkeit an der Injektionsstelle (Kinder von 6 Monaten bis 11 Jahren), Ermüdung; Kopfschmerzen; Muskelschmerzen; Gelenkschmerzen; Schüttelfrost; Fieber; Durchfall, Reizbarkeit & Schläfrigkeit (6 Monate bis unter 2 Jahre). Häufig: Übelkeit; Erbrechen (‚sehr häufig‘ bei Schwangeren ab 18 Jahren und bei immungeschwächten Personen im Alter von 2 bis 18 Jahren); Rötung an der Injektionsstelle (‚sehr häufig‘ bei Kindern von 6 Monaten bis 11 Jahren und bei immungeschwächten Personen ab 2 Jahren); vergrößerte Lymphknoten (häufiger beobachtet nach der Auffrischungsdosis). Gelegentlich: Unwohlsein; Schwächegefühl oder Energiemangel/Schläfrigkeit; Armschmerzen; Schlaflosigkeit; Jucken an der Injektionsstelle; allergische Reaktionen wie Ausschlag (‚häufig‘ bei Kindern von 6 Monaten bis unter 2 Jahren) oder Juckreiz; verminderter Appetit (‚sehr häufig‘ bei Kindern von 6 Monaten bis unter 2 Jahren); Schwindelgefühl; starkes Schwitzen; nächtliche Schweißausbrüche. Selten: vorübergehendes, einseitiges Herabhängen des Gesichtes; allergische Reaktionen wie Nesselsucht oder Schwellung des Gesichts. Sehr selten: Entzündung des Herzmuskels (Myokarditis) oder Entzündung des Herzbeutels (Perikarditis), die zu Atemnot, Herzklopfen oder Thoraxschmerzen führen können. Häufigkeit nicht bekannt: schwere allergische Reaktionen; ausgedehnte Schwellung der geimpften Gliedmaße; Anschwellen des Gesichts (ein geschwollenes Gesicht kann bei Patienten auftreten, denen in der Vergangenheit dermatologische Filler im Gesichtsbereich injiziert wurden); eine Hautreaktion, die rote Flecken oder Stellen auf der Haut verursacht, die wie ein Ziel oder eine Zielscheibenmitte mit einer dunkelroten Mitte aussehen können, das von hellroten Ringen umgeben ist (Erythema multiforme); ungewöhnliches Gefühl in der Haut, wie Prickeln oder Kribbeln (Parästhesie); vermindertes Gefühl oder verminderte Empfindlichkeit, insbesondere der Haut (Hypoästhesie); starke Menstruationsblutungen (die meisten Fälle schienen nicht schwerwiegend und vorübergehend zu sein). Verschreibungspflichtig. Stand der Informationen: Juli 2026. BioNTech Manufacturing GmbH, An der Goldgrube 12, 55131 Mainz. Weitere Informationen, Warnhinweise und Vorsichtsmaßnahmen sind der Fachinformation zu entnehmen. www.comirnatyglobal.com.

Das schwarze gleichseitige Dreieck ▼ bedeutet, dass ein zusätzliches Monitoring erforderlich ist, um etwaige Nebenwirkungen zu erfassen. Dies ermöglicht eine schnelle Identifizierung von neuen Sicherheitsinformationen. Einzelpersonen können helfen, indem sie alle Nebenwirkungen, die sie möglicherweise bekommen, melden. Nebenwirkungen können an EudraVigilance oder direkt an BioNTech per E-Mail an [email protected], Telefon +49 6131 9084 0 oder über die Webseite http://www.biontech.de/ gemeldet werden.

Über Pfizer: Breakthroughs That Change Patients’ Lives
Bei Pfizer setzen wir die Wissenschaft und unsere globalen Ressourcen ein, um den Menschen Therapien anzubieten, die ihr Leben verlängern und deutlich verbessern. Wir wollen den Standard für Qualität, Sicherheit und Nutzen bei der Entdeckung, Entwicklung und Herstellung innovativer Medikamente und Impfstoffe setzen. Jeden Tag arbeiten Pfizer-Mitarbeiter weltweit daran, das Wohlbefinden, die Prävention, Behandlungen und Heilung von schwerwiegenden Erkrankungen voranzutreiben. Als eines der weltweit führenden innovativen biopharmazeutischen Unternehmen sehen wir es als unsere Verantwortung, mit Gesundheitsversorgern, Regierungen und lokalen Gemeinschaften zusammenzuarbeiten, um den Zugang zu einer zuverlässigen und erschwinglichen Gesundheitsversorgung auf der ganzen Welt zu unterstützen. Seit mehr als 175 Jahren arbeiten wir daran, etwas für all jene zu bewirken, die auf uns zählen. Wir veröffentlichen regelmäßig Informationen auf unserer Website unter www.Pfizer.com, die für Investoren wichtig sein könnten. Mehr Informationen über Pfizer finden Sie unter www.Pfizer.com, auf X unter @Pfizer und @Pfizer News, LinkedIn, YouTube und auf Facebook unter Facebook.com/Pfizer.

Offenlegungshinweis von Pfizer
Die in dieser Pressemitteilung enthaltenen Informationen entsprechen dem Stand vom 29. Juli 2026. Pfizer übernimmt keine Verpflichtung, die in dieser Mitteilung enthaltenen zukunftsgerichteten Aussagen aufgrund neuer Informationen oder zukünftiger Ereignisse oder Entwicklungen zu aktualisieren.

Diese Pressemitteilung enthält bestimmte in die Zukunft gerichtete Aussagen bezüglich des Pfizer-BioNTech COVID-19-Impfstoffs, einschließlich seiner potenziellen Vorteile, der Herstellung und Versorgung, der Erwartungen hinsichtlich der Nachfrage nach COVID-19-Impfungen sowie einer Genehmigung durch die Europäische Kommission zur Aktualisierung der Marktzulassung für den Pfizer-BioNTech COVID-19-Impfstoff, um die XFG-Variante der JN.1-Linie für die Saison 2026–2027 zu adressieren, welche erhebliche Risiken und Ungewissheiten beinhalten, die dazu führen können, dass die tatsächlichen Ergebnisse wesentlich von den in solchen Aussagen zum Ausdruck gebrachten oder implizierten Ergebnissen abweichen. Zu den Risiken und Ungewissheiten gehören unter anderem: Ungewissheiten bezüglich des kommerziellen Erfolgs des Pfizer-BioNTech COVID-19-Impfstoffs; Ungewissheiten, die mit Forschung und Entwicklung verbunden sind, einschließlich der Fähigkeit, erwartete klinische Endpunkte, Zeitpunkte für den Beginn und/oder den Abschluss klinischer Studien, Zeitpunkte für die Einreichung von Zulassungsanträgen bei den Behörden, Zeitpunkte für die behördliche Zulassung und/oder die Zeitpunkte für die Markteinführung einzuhalten, sowie die Möglichkeit ungünstiger neuer klinischer Daten und weiterer Analysen bestehender klinischer Daten; das Risiko, dass klinische Studiendaten unterschiedlichen Interpretationen und Bewertungen durch Zulassungsbehörden unterliegen; die Frage, ob die Zulassungsbehörden mit dem Design und den Ergebnissen unserer klinischen Studien zufrieden sein werden; ob und wann Anträge bei Zulassungsbehörden in bestimmten Rechtsordnungen für den Pfizer-BioNTech COVID-19-Impfstoff für eine potenzielle Indikation, einschließlich der COVID-19-Impfstoffformulierung für 2026-2027, eingereicht werden können; ob und wann solche Anträge für den Pfizer-BioNTech COVID-19-Impfstoff, die möglicherweise anhängig sind oder eingereicht werden, von den Zulassungsbehörden genehmigt werden, was von unzähligen Faktoren abhängt, darunter die Beurteilung, ob die Vorteile des Produkts die bekannten Risiken überwiegen sowie der Bestimmung der Wirksamkeit des Produkts und, falls genehmigt, ob der Pfizer-BioNTech COVID-19-Impfstoff kommerziell erfolgreich sein wird; Entscheidungen von Zulassungsbehörden, die sich auf die Kennzeichnung, Herstellungsverfahren, Sicherheit und/oder andere Faktoren auswirken, die die Verfügbarkeit oder das kommerzielle Potenzial des Pfizer-BioNTech COVID-19-Impfstoffs beeinflussen können; Risiken und Ungewissheiten im Zusammenhang mit möglichen Änderungen der Impfstoff- oder sonstigen Gesundheitspolitik in der EU, den Vereinigten Staaten von Amerika und anderen Ländern; das Risiko, dass die Nachfrage nach bestimmten Produkten zurückgeht, nicht länger besteht oder nicht den Erwartungen entsprechen könnte, was zu niedrigeren Einnahmen oder einem Überschuss an Lagerbeständen und/oder im Vertriebskanal oder anderen unvorhergesehenen Aufwendungen führen könnte; Ungewissheiten in Bezug auf Empfehlungen und Abdeckung sowie die Akzeptanz von Impfstoffen, Auffrischungsimpfungen, Behandlungen oder Kombinationen davon in der Bevölkerung; Risiken in Bezug auf unsere Fähigkeit, unsere Umsatzprognosen für den Pfizer-BioNTech COVID-19-Impfstoff oder potenzielle zukünftige COVID-19-Impfstoffe präzise antizipieren zu können oder zu erreichen; Risiken und Ungewissheiten im Zusammenhang mit erlassenen oder künftigen Durchführungsverordnungen (Executive Orders) oder anderen neuen oder geänderten Gesetzen oder Vorschriften; Unsicherheiten hinsichtlich der Auswirkungen von COVID-19 auf das Geschäft, den Betrieb und die Finanzergebnisse von Pfizer sowie die wettbewerbliche Entwicklungen.

Weitere Ausführungen zu Risiken und Ungewissheiten finden Sie im Jahresbericht des am 31. Dezember 2025 endenden Geschäftsjahres von Pfizer im sog. „Form 10-K“ sowie in weiteren Berichten im sog. „Form 10-Q“, einschließlich der Abschnitte „Risk Factors“ und „Forward-Looking Information and Factors That May Affect Future Results”, sowie in den zugehörigen weiteren Berichten im sog. „Form 8-K“, welche bei der U.S. Securities and Exchange Commission eingereicht wurden und unter www.sec.gov und www.Pfizer.com abrufbar sind.

Über BioNTech
BioNTech ist ein globales innovatives Biopharma-Unternehmen, das bei der Entwicklung von Therapien gegen Krebs und andere schwere Erkrankungen Pionierarbeit leistet. In der Onkologie möchte BioNTech die Behandlungsmöglichkeiten für Menschen mit Krebs nachhaltig verbessern. Das Unternehmen hat sich zum Ziel gesetzt, innovative Arzneimittel mit tumorübergreifendem oder synergistischem Potenzial zu entwickeln, um Krebs in all seinen Facetten und entlang des gesamten Krankheitsverlaufs – von den frühen bis zu den fortgeschrittenen Krankheitsstadien – zu adressieren. BioNTechs wachsendes Portfolio an onkologischen Produktkandidaten in der späten klinischen Entwicklung umfasst innovative Immunmodulatoren, Antikörper-Wirkstoff-Konjugate und mRNA-Krebsimmuntherapien. BioNTech arbeitet Seite an Seite mit weltweit renommierten und spezialisierten Kollaborationspartnern, darunter Bristol Myers Squibb, Duality Biologics, Genentech (ein Unternehmen der Roche Gruppe), Genmab, MediLink, OncoC4 und Pfizer.

Weitere Information finden Sie unter: www.BioNTech.de.

Zukunftsgerichtete Aussagen von BioNTech
Diese Pressemitteilung enthält bestimmte in die Zukunft gerichtete Aussagen von BioNTech im Rahmen des angepassten Private Securities Litigation Reform Act von 1995, einschließlich, aber nicht begrenzt auf ausdrückliche oder implizite Aussagen bezogen auf: BioNTechs Bemühungen, COVID-19 zu bekämpfen; die Kollaboration zwischen BioNTech und Pfizer; behördliche Anträge und behördliche Genehmigungen oder Zulassungen, einschließlich einer Genehmigung der Europäischen Kommission zur Aktualisierung der Marktzulassung für den COVID-19-Impfstoff von Pfizer-BioNTech, um die XFG-Variante der JN.1-Linie für die Saison 2026-2027 abzudecken; Erwartungen hinsichtlich Herstellung, Vertrieb und Versorgung; qualitative Bewertungen verfügbarer Daten und Erwartungen möglicher Vorteile, einschließlich der Immunantwort des angepassten Impfstoffs auf mehrere SARS-CoV-2-Linien, einschließlich der XFG-Variante der JN.1-Linie sowie andere zirkulierende Sublinien; den Annahmen hinsichtlich zu erwartender Anpassungen in der COVID-19-Impfstoffnachfrage, einschließlich Veränderungen des Umfelds für Bestellungen; und der erwarteten behördlichen Empfehlungen zur Anpassung von Impfstoffen an neue Varianten oder Sublinien. In manchen Fällen können die zukunftsgerichteten Aussagen durch Verwendung von Begriffen wie „wird“, „kann“, „sollte“, „erwartet“, „beabsichtigt“, „plant“, „zielt ab“, “antizipiert”, „schätzt“, „glaubt“, „prognostiziert“, „potenziell“, „setzt fort“ oder die negative Form dieser Begriffe oder einer anderen vergleichbaren Terminologie identifiziert werden, allerdings müssen nicht alle zukunftsgerichteten Aussagen diese Wörter enthalten.

Die zukunftsgerichteten Aussagen in dieser Pressemitteilung basieren auf den aktuellen Erwartungen und Einschätzungen von BioNTech hinsichtlich zukünftiger Ereignisse, und sind weder Versprechen noch Garantien und sollten nicht als solche angesehen werden, da sie einer Reihe von bekannten und unbekannten Risiken, Unsicherheiten und anderen Faktoren unterliegen, von denen viele außerhalb der Kontrolle von BioNTech liegen und die dazu führen könnten, dass die tatsächlichen Ergebnisse wesentlich von denen abweichen, die in diesen zukunftsgerichteten Aussagen ausdrücklich oder implizit zum Ausdruck gebracht werden. Diese Risiken und Ungewissheiten beinhalten, sind aber nicht beschränkt auf: die Unwägbarkeiten, die mit Forschung und Entwicklung verbunden sind, einschließlich der Fähigkeit, die erwarteten klinischen Endpunkte, die Termine für Beginn und/oder Abschluss klinischer Studien, die Termine für die Einreichung von Zulassungen bei den Behörden, die Termine für die behördliche Zulassung und/oder die Termine für die Markteinführung zu erreichen, sowie die Risiken im Zusammenhang mit präklinischen und klinischen Daten, einschließlich der in dieser Pressemitteilung veröffentlichen Daten, und einschließlich der Möglichkeit ungünstiger neuer präklinischer, klinischer oder Sicherheitsdaten und weitere Analysen bereits existierender präklinischer, klinischer oder Sicherheitsdaten; die Art der klinischen Daten, die einer ständigen Überprüfung durch Peer-Review, einer behördlichen Prüfung und einer Marktinterpretation unterliegen; BioNTechs Preis- und Kostenübernahmeverhandlungen mit staatlichen Behörden, privaten Krankenversicherungen und anderen Drittparteien; die künftige kommerzielle Nachfrage und der medizinische Bedarf an Erst- oder jährlichen Auffrischungsdosen mit einem COVID-19-Impfstoff; die Auswirkungen von Zöllen und Eskalationen in der Handelspolitik; die Verfügbarkeit von Rohmaterial zur Herstellung von Impfstoffen; die Formulierung unseres Impfstoffs, dem Dosierungsschema und den damit verbundenen Anforderungen an Lagerung, Vertrieb und Verabreichung, einschließlich der Risiken im Zusammenhang mit der Lagerung und Handhabung nach Lieferung; der Wettbewerb durch andere COVID-19-Impfstoffe oder bezogen auf BioNTechs weitere Produktkandidaten, einschließlich solcher mit anderen Wirkmechanismen und anderen Herstellungs- und Vertriebsbedingungen, basierend unter anderem auf Wirksamkeit, Kosten, Lager- und Lieferbedingungen, die Breite der zugelassenen Anwendung, Nebenwirkungsprofil und Beständigkeit der Immunantwort; die Fähigkeit, Empfehlungen von beratenden oder technischen Impfstoffausschüssen und anderen Gesundheitsbehörden zu erhalten und die Ungewissheit hinsichtlich der kommerziellen Auswirkungen solcher Empfehlungen; den Zeitpunkt und BioNTechs Fähigkeit, behördliche Zulassungen für ihre Produktkandidaten zu erhalten und aufrechtzuerhalten; die Fähigkeit von BioNTechs COVID-19-Impfstoffen, COVID-19 zu verhindern, das von aufkommenden Virusvarianten verursacht wird; BioNTechs Fähigkeit, Forschungsmöglichkeiten zu erkennen und Prüfpräparate zu identifizieren und zu entwickeln; die Fähigkeit und Bereitschaft von BioNTechs Kooperationspartnern, die Forschungs- und Entwicklungsaktivitäten in Bezug auf BioNTechs Produktkandidaten und Prüfpräparate fortzusetzen; die Auswirkungen von COVID-19 auf Entwicklungsprogramme, Lieferketten, Kooperationspartner und die finanzielle Leistungsfähigkeit von BioNTech; unvorhergesehene Sicherheitsbelange und potenzielle Ansprüche, die angeblich durch den Einsatz von BioNTechs COVID-19-Impfstoff sowie anderer von BioNTech entwickelter oder hergestellter Produkte und Produktkandidaten auftreten; die Fähigkeit BioNTechs und ihrer Kollaborationspartner, BioNTechs COVID-19-Impfstoff zu kommerzialisieren und zu vermarkten und, falls sie zugelassen werden, BioNTechs Produktkandidaten; BioNTechs Fähigkeit, ihre Entwicklung und verbundenen Ausgaben zu steuern; regulatorische Entwicklungen in den USA und anderen Ländern; die Fähigkeit, BioNTechs Produktionskapazitäten effektiv zu skalieren und ihre Produkte und Produktkandidaten herzustellen; Risiken in Bezug auf das globale Finanzsystem und die Märkte; und andere Faktoren, die BioNTech derzeit nicht bekannt sind.

Den Leserinnen und Lesern wird empfohlen, die Risiken und Unsicherheiten unter „Risk Factors“ in BioNTechs Bericht (Form 6-K) für das am 31. März 2026 endende Quartal und in den darauffolgend bei der U.S. Securities and Exchange Commission (SEC) eingereichten Dokumenten zu lesen. Sie sind auf der Website der SEC unter www.sec.gov verfügbar. Diese zukunftsgerichteten Aussagen gelten nur zum Zeitpunkt der Veröffentlichung dieser Pressemitteilung. Außerhalb rechtlicher Verpflichtungen übernimmt BioNTech keinerlei Verpflichtung, solche in die Zukunft gerichteten Aussagen nach dem Datum dieser Pressemitteilung zu aktualisieren, um sie an die tatsächlichen Ergebnisse oder Änderungen der Erwartungen anzupassen.

Hinweis: Dies ist eine Übersetzung der englischsprachigen Pressemitteilung. Im Falle von Abweichungen zwischen der deutschen und der englischen Version hat ausschließlich die englische Fassung Gültigkeit.

KONTAKTE

Pfizer:
Medienanfragen
+1 (212) 733-1226
[email protected]

Investoranfragen
+1 (212) 733-4848
[email protected]

BioNTech:
Medienanfragen
Jasmina Alatovic
[email protected]

Investoranfragen
Dr. Douglas Maffei
[email protected]

Fußnoten:
1 ETF. ETF empfiehlt Aktualisierung der COVID-19-Impfstoffe, um XFG-Variante abzudecken. Aktualisiert am 29. Mai 2026. Abgerufen am 25. Juni 2026. https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19-vaccines-target-xfg-variant
2 Vaccines and Related Biological Products Advisory Committee. Meeting-Präsentation - COVID-19-Impfstoffformulierung für 2026-2027: Unterstützende Daten von Pfizer/BioNTech. 28. Mai 2026. Abgerufen am 25. Juni 2026. https://www.fda.gov/media/192765/download

MGM Resorts (MGM - Free Report) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.63 per share. This compares to earnings of $0.79 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -6.35%. A quarter ago, it was expected that this casino and resort operator would post earnings of $0.56 per share when it actually produced earnings of $0.49, delivering a surprise of -12.5%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

MGM, which belongs to the Zacks Gaming industry, posted revenues of $4.45 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 0.37%. This compares to year-ago revenues of $4.4 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

MGM shares have added about 26.6% since the beginning of the year versus the S&P 500's gain of 8.5%.

What's Next for MGM?While MGM has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for MGM was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.27 on $4.31 billion in revenues for the coming quarter and $1.99 on $17.75 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Gaming is currently in the bottom 25% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Light & Wonder (LNWO - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.

This instant-win lottery ticket maker is expected to post quarterly earnings of $1.75 per share in its upcoming report, which represents a year-over-year change of +10.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Light & Wonder's revenues are expected to be $846.45 million, up 4.6% from the year-ago quarter.

Kraft Heinz (KHC - Free Report) ended the recent trading session at $27.62, demonstrating a +1.17% change from the preceding day's closing price. The stock outpaced the S&P 500's daily loss of 1.52%. At the same time, the Dow lost 2.19%, and the tech-heavy Nasdaq lost 1.74%.

Heading into today, shares of the processed food company with dual headquarters in Pittsburgh and Chicago had gained 15.58% over the past month, outpacing the Consumer Staples sector's gain of 2.93% and the S&P 500's gain of 1.92%.

The upcoming earnings release of Kraft Heinz will be of great interest to investors. The company's earnings report is expected on August 5, 2026. It is anticipated that the company will report an EPS of $0.53, marking a 23.19% fall compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $6.16 billion, down 2.99% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $2.07 per share and a revenue of $24.45 billion, demonstrating changes of -20.38% and -1.96%, respectively, from the preceding year.

Investors should also pay attention to any latest changes in analyst estimates for Kraft Heinz. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.2% higher. Currently, Kraft Heinz is carrying a Zacks Rank of #2 (Buy).

From a valuation perspective, Kraft Heinz is currently exchanging hands at a Forward P/E ratio of 13.18. This valuation marks a discount compared to its industry average Forward P/E of 13.68.

The Food - Miscellaneous industry is part of the Consumer Staples sector. This group has a Zacks Industry Rank of 210, putting it in the bottom 15% of all 250+ industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Item 1 of 2 A man looks at a Patriot Advanced Capability (PAC-3) Missile Segment Enhancement (MSE) model by Lockheed Martin at an international military fair in Kielce, Poland September 7, 2017. REUTERS/Kacper Pempel/File Photo

[1/2]A man looks at a Patriot Advanced Capability (PAC-3) Missile Segment Enhancement (MSE) model by Lockheed Martin at an international military fair in Kielce, Poland September 7, 2017. REUTERS/Kacper... Purchase Licensing Rights, opens new tab Read more

WASHINGTON, July 29 (Reuters) - The U.S. Army awarded Lockheed Martin (LMT.N), opens new tab a contract worth up to $58.6 billion to produce Patriot interceptor missiles, the Pentagon ​said on Wednesday, as conflicts in Iran and Ukraine strain U.S. weapons stockpiles.

The U.S. ‌has supplied large quantities of weapons to allies while also using munitions in its own military operations in Iran, raising concerns about inventories of key air defense and precision-guided weapons.

The Reuters Iran Briefing newsletter keeps you informed with the latest developments and analysis of the Iran war. Sign up here.

The Lockheed award converts a previous one-year deal worth $4.7 ​billion awarded in April into a seven-year draft agreement, creating a multiyear procurement plan ​for the interceptors from fiscal 2026 through 2032, the Army said.

Pentagon negotiators are ⁠pressing contractors to move much faster, with tentative production agreements struck earlier this year at the center of ​efforts to increase missile output. The administration of President Donald Trump has also steadily increased pressure on ​defense contractors to prioritize production over shareholder payouts. Trump signed an executive order in January to identify contractors deemed to be underperforming on government contracts while continuing to distribute profits to shareholders.

Industry executives have welcomed the production agreements, but said ​Congress must first appropriate funding before companies can invest more heavily in components and production capacity.

Exact ​terms and delivery dates for many Pentagon munitions deals are still under negotiation.

A similar framework deal had been struck ‌with ⁠Raytheon's parent company RTX (RTX.N), opens new tab to boost production of Tomahawk cruise missiles from the current rate of about 60 per year for the U.S. to eventually 1,000 units annually.

Lockheed, a Bethesda, Maryland-based defense contractor, said the funding would allow it to follow through on a promise to triple PAC-3 MSE production capacity ​by the end of ​2030 and increase jobs ⁠at its Camden, Arkansas, plant by 50%, to about 1,850 from 1,200. Lockheed previously announced Patriot PAC-3 missile interceptor production would go to 2,000 units ​annually.

Lockheed Martin said it is investing $8 billion to $9 billion through 2030 to ​modernize more than ⁠20 U.S. facilities, including new munitions centers in Alabama and Arkansas.

PAC-3 MSE is a hit-to-kill interceptor used within the Patriot air defense system to counter ballistic missiles, cruise missiles and aircraft.

The Center for Strategic and ⁠International ​Studies, a Washington-based think tank, estimated this week that the ​U.S. military has fewer than 1,000 Patriot interceptors on hand and fewer than 250 THAAD interceptors -- two key air defense systems. Both have ​seen recent heavy use in the Middle East.

Reporting by Mike Stone in Washington; editing by Chris Sanders

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Mike Stone is a Reuters reporter covering the U.S. arms trade and defense industry. Most recently Mike has been focused on the Golden Dome missile defense shield. Mike also spends a lot of his time writing on Ukraine and how industry has adapted, or faltered as it supports that conflict. Mike, a New Yorker, has extensively covered how the U.S. has supplied Ukraine with weapons, the cadence, decisions and milestones that have had battlefield impacts. Before his time in Washington Mike’s coverage focused on mergers and acquisitions for oil and gas companies, financial institutions, defense companies, consumer product makers, retailers, real estate giants, and telecommunications companies.